Yuki Matsuda

BACKGROUND: Treatment of depression in patients with cancer requires individualized decision-making considering physical symptoms, drug interactions, adverse effects, treatment burden, and acceptability. We report a patient with persistent depression after colorectal cancer treatment, in whom pharmacotherapy was constrained by insufficient efficacy and tolerability, improvement with modified electroconvulsive therapy (mECT) was temporary, and reintroduction of mECT was difficult. She subsequently received repetitive transcranial magnetic stimulation (rTMS). CASE PRESENTATION: A woman in her 60s developed depression after emergency surgery for lower gastrointestinal perforation caused by descending colon cancer and later developed chemotherapy-induced peripheral neuropathy (CIPN) after postoperative chemotherapy. Pharmacotherapy produced insufficient improvement. Although 10 mECT sessions led to improvement, symptoms recurred after discharge. Reintroduction of mECT was not possible because of strong fear of the treatment and general anesthesia. She was referred to our hospital and received 27 rTMS sessions without changes in psychotropic medication. Her 17-item Hamilton Depression Rating Scale and Clinical Global Impressions-Severity (CGI-S) scores improved from 19 to 8 and from 4 to 1, respectively, whereas the pain Numerical Rating Scale score remained 8. Behavior and daily functioning also improved. Six months after treatment, limb discomfort persisted, but she could still perform household chores and go out. The referring physician rated the CGI-S score as 1. CONCLUSION: When pharmacotherapy for depression after cancer treatment is constrained by insufficient efficacy or tolerability, and the benefit of mECT is transient or its reintroduction is difficult, rTMS may be considered as a treatment option.

Major depressive disorder is a leading cause of disability worldwide, and many patients fail to achieve sustained remission with first-line pharmacotherapy or psychotherapy. This unmet need has traditionally been framed as treatment-resistant depression (TRD), defined by an inadequate response to antidepressant treatment. Within this context, neuromodulation has assumed an increasingly important role by providing mechanistically distinct interventions when medication-based approaches are insufficient, poorly tolerated, or too slow. In this expert opinion article, we present a targeted, clinically oriented review of two established neuromodulation therapies for depression, electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS), encompassing conventional repetitive TMS (rTMS), deep TMS, and theta-burst stimulation (TBS), as well as magnetic seizure therapy (MST), the most clinically advanced investigational convulsive modality. ECT remains the benchmark treatment for severe, urgent, psychotic, or otherwise refractory depression due to its rapid and robust efficacy, although its use is limited by anesthesia requirements, cognitive adverse effects, and associated stigma. TMS has the strongest evidence base among nonconvulsive neuromodulation treatments, with pivotal sham-controlled multicenter trials supporting conventional rTMS and deep TMS, while TBS protocols are improving feasibility, access, and scalability. MST is conceptually appealing as a more focal convulsive treatment designed to preserve antidepressant efficacy while reducing cognitive burden; recent Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression (CREST-MST) data have strengthened its evidence base, but its routine clinical role remains to be defined through regulatory approval, durability data, and implementation evidence. We argue that future progress will depend not only on the development of new stimulation protocols but also on improved clinical sequencing, patient selection, and maintenance strategies that help sustain acute gains. The concept of difficult-to-treat depression (DTD) broadens the clinical framework beyond antidepressant nonresponse to include persistent burden, partial response, tolerability constraints, functional impairment, and patient-centered goals. This perspective may inform earlier and more strategic use of neuromodulation, although most randomized controlled trials remain focused on TRD. Further studies are needed to determine whether DTD-based approaches improve real-world outcomes. Advances are likely to arise from integrating protocol refinement, individualized targeting, scalable home-based approaches, depression-relevant extensions such as bipolar depression, and durable maintenance strategies rather than identifying a single universally superior modality.

This article relates to Time zero alignment in target trial emulation of VMAT2 inhibitors versus anticholinergics for tardive dyskinesia.

This article relates to Model choice in meta-analysis should not be driven by Cochran's Q test.